Interpace Biosciences Completes Its Pharma Services Business Sale to Flagship Biosciences, Inc.

The Company announces the complete sale of the pharma services business which could impact the IDXG Stock. For more information regarding the Company's business, visit OTC Wiki. 

Interpace Biosciences Inc is a leading company that specializes in enabling personalized medicinal products. This Company has closed a definitive asset purchase agreement under the Flagship of Biosciences Inc. It has acquired the Company's pharma services business. 

The Company will also use the proceeds from the transaction for working capital requirements and investments to help drive the growth of its molecular diagnostics business. The president and CEO of the Company also announced that with the completion of the multiple transactions, we expect the Company to make progress.

Moreover, the company's driven ash flow will focus on molecular diagnostics that the Company is offering the best in class solutions and other diagnostic insights. Besides providing the IDXG Stock, the Company determines the presence of certain cancers in clinicians and their patients. 

About Interpace Biosciences:

Interpace Biosciences is an emerging leader in enabling personalized medicine. Besides offering the common stock under the name IDXG Stock, it offers specialized services along the therapeutic value chain, including early diagnosis and prognostic planning.

The multiple clinical services throughout the Interpace diagnostic provides the clinical use of the molecular diagnostic test, bioinformatics and pathology services for evaluation of the factor of risk and cancer.

It also leverages the latest technology in personalizing the patients and their management. For the diagnosis of thyroid cancer from the thyroid nodules, the Company is utilizing the next-generation sequencing assay. It also proprietary gene expression assay and much more. 

A financial statement analysis of IDXG Stock indicates that the short-term assets of this Company cover the short-term liabilities. On the other hand, all the long-term assets of this Company are also exceeding and hence covering the long-term liabilities. Moreover, the IDXG Stock holds the current price of 2.05 US dollars on September 21, 2022.